SCHEMBL5394243

SCHEMBL5394243

COc1ccc(CN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)NCc2ccccc2OC)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.52
TAS1R1 Q7RTX1 1/20 0.52
HPGD P15428 4/20 0.52
ALDH1A1 P00352 4/20 0.52
HTT P42858 2/20 0.52
GAA P10253 1/20 0.52
PKM P14618 1/20 0.52
KCNK3 O14649 1/20 0.49
KCNK5 O95279 1/20 0.49
KCNA5 P22460 1/20 0.49
KCNK17 Q96T54 1/20 0.49
KCNK9 Q9NPC2 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
KDM4E B2RXH2 2/20 0.48
RCE1 Q9Y256 1/20 0.48
PLA2G1B P04054 1/20 0.48
ATG4B Q9Y4P1 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
LPAR1 Q92633 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5394988 0.94 HPGD (0.56) TAS1R3TAS1R1HPGDALDH1A1HTT
SCHEMBL5402332 0.93 PLA2G1B (0.57) TAS1R3TAS1R1HPGDALDH1A1HTT
SCHEMBL5405730 0.92 TAS1R3 (0.52) TAS1R3TAS1R1HPGDALDH1A1HTT
SCHEMBL5397765 0.91 HDAC1 (0.49) TAS1R3TAS1R1HPGDALDH1A1HTT
SCHEMBL5403175 0.90 HDAC1 (0.59) HPGDALDH1A1HDAC1HDAC6TDP1
SCHEMBL5401992 0.90 KCNK3 (0.55) TAS1R3TAS1R1ALDH1A1HTTKCNK3
SCHEMBL5409503 0.90 MAPK8 (0.51) TAS1R3TAS1R1ALDH1A1HTTKCNK3
SCHEMBL5397479 0.89 HDAC1 (0.61) HPGDALDH1A1HDAC1HDAC6TDP1
SCHEMBL5407093 0.89 HDAC1 (0.61) HPGDALDH1A1HDAC1HDAC6TDP1
SCHEMBL5403255 0.89 KCNA5 (0.56) TAS1R3TAS1R1HPGDALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB TAS1R3 4642/4885TAS1R1 4377/4885HPGD 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.